389 related articles for article (PubMed ID: 30096090)
1. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
Gayam V; Tiongson B; Khalid M; Mandal AK; Mukhtar O; Gill A; Garlapati P; Shrestha B; Khalid M; Chakraborty S; Guss D; Sherigar J; Mansour M; Mohanty S
Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1200-1207. PubMed ID: 30096090
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
3. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
Hu C; Yuan G; Liu J; Huang H; Ren Y; Li Y; Chen X; Li W; Wu T; Deng H; Peng Y; Zhang YY; Zhou Y
Can J Gastroenterol Hepatol; 2018; 2018():3908767. PubMed ID: 30538973
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
7. The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.
Townshend-Bulson L; Roik E; Barbour Y; Bruden DJT; Homan CE; Espera HGF; Stevenson TJ; Hewitt AM; Rhodes W; Gove JE; Plotnik JN; Snowball MM; McGilvray J; Simons BC; Johnston JM; McMahon BJ
PLoS One; 2021; 16(12):e0260970. PubMed ID: 34855920
[TBL] [Abstract][Full Text] [Related]
8. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
[TBL] [Abstract][Full Text] [Related]
13. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
14. Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
Beck KR; Kim N; Khalili M
Dig Dis Sci; 2016 Dec; 61(12):3602-3608. PubMed ID: 27743164
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
[TBL] [Abstract][Full Text] [Related]
16. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
[TBL] [Abstract][Full Text] [Related]
18. [Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].
Li JP; Chen XF; Yan Q; Zhang YJ; Xie ZW; Xia Y; Guan YJ
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):831-837. PubMed ID: 33105927
[No Abstract] [Full Text] [Related]
19. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand.
Sirinawasatien A; Techasirioangkun T
PLoS One; 2020; 15(2):e0229517. PubMed ID: 32106270
[TBL] [Abstract][Full Text] [Related]
20. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
Tao YC; Deng R; Wang ML; Lv DD; Yuan M; Wang YH; Chen EQ; Tang H
Virol J; 2018 Oct; 15(1):150. PubMed ID: 30285800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
